RBC Capital Mkts has recently reduced Sangamo Therapeutics Inc (SGMO) stock to Sector Perform rating, as announced on November 3, 2023, according to Finviz. Earlier, on April 28, 2023, BofA Securities had reduced the stock from a Neutral to Underperform, setting a price target of $1.50 for SGMO stock. Wedbush also raised Outperform rating with a price target of $16. Additionally, BofA Securities reduced Neutral rating on January 6, 2023, with a target price of $5. Wedbush analysts, in their report published on June 13, 2022, also resumed Neutral rating and set a price target of $5 for Sangamo Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sangamo Therapeutics Inc (SGMO) Stock Trading Recap
On Tuesday, Sangamo Therapeutics Inc (SGMO) stock saw a decline, ending the day at $2.15 which represents a decrease of $-0.21 or -8.90% from the prior close of $2.36. The stock opened at $2.37 and touched a low of $2.07 during the day, reaching a high of $2.37. The volume of shares traded was 4.65 million falling short of the average volume of 7.33 million.
Sponsored
SGMO Stock Performance and Moving Averages
In recent trading, Sangamo Therapeutics Inc (SGMO) stock price has shown some volatility, fluctuating 10.82% over the last five trades and 14.36% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 278.79%, and it has gained 169.36% in the previous three months. Currently, SGMO is trading at -4.78%, 35.14%, and 136.30% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, SGMO, a Healthcare sector stock, is trading -32.37% below its 52-week high but remains 607.24% above its 52-week low. The Average True Range (ATR) (14 days) of 0.28 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Sangamo Therapeutics Inc’s Profitability and Valuation Ratios
Sangamo Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of -256.68% and a profit margin of -260.33%, with a gross margin of 278.79%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Sangamo Therapeutics Inc’s market capitalization stands at $448.59 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 8.58, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 11.46, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 4.59% of Sangamo Therapeutics Inc (SGMO)’s shares, while financial institutions hold 27.00%.
